Wei Wang to Proto-Oncogene Proteins c-mdm2
This is a "connection" page, showing publications Wei Wang has written about Proto-Oncogene Proteins c-mdm2.
Connection Strength
5.189
-
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future. Pharmacol Rev. 2024 May 02; 76(3):414-453.
Score: 0.881
-
Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action. Cells. 2020 Jul 01; 9(7).
Score: 0.676
-
Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy. Cells. 2020 05 09; 9(5).
Score: 0.669
-
Targeting MDM2 for novel molecular therapy: Beyond oncology. Med Res Rev. 2020 05; 40(3):856-880.
Score: 0.642
-
MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. Cancer Lett. 2019 09 10; 459:156-167.
Score: 0.627
-
Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. Cancer Res. 2018 10 01; 78(19):5656-5667.
Score: 0.597
-
Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms. Carcinogenesis. 2018 07 30; 39(8):1026-1036.
Score: 0.591
-
Structural studies of antitumor compounds that target the RING domain of MDM2. Protein Sci. 2022 Aug; 31(8):e4367.
Score: 0.195
-
Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope. Cancer Lett. 2021 01 01; 496:16-29.
Score: 0.172
-
Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway. Prog Mol Biol Transl Sci. 2017; 151:195-216.
Score: 0.139